Just caught Neuronetics (STIM) earnings and the stock is popping off. They reported Q4 revenue of $41.8 million, up 86% year-over-year, and the market loved it - stock jumped nearly 30% in premarket. The real growth driver here is their NeuroStar system, which is basically a non-invasive treatment for major depression and OCD. Pretty interesting space honestly. Their OCD treatment line alone saw massive adoption with 49 systems shipped in Q4. What caught my attention is the revenue breakdown - NeuroStar system sales hit $18.3 million (was only $3.8M last year), and their clinic operations revenue jumped to $23.5 million from $4.4 million. That's the kind of growth trajectory that gets investors excited. For the full year, they're sitting at $149.2 million revenue, up 99% from 2024. Even on an adjusted basis, stripping out one-time stuff, it's still solid 15% growth year-over-year. They also ended 2025 with $34.1 million in cash and actually turned positive operating cash flow in Q4, which is usually a good sign. CEO mentioned they're maintaining a strong balance sheet heading into 2026. They'll drop the full financial details on March 17, but based on these prelims, the momentum looks real. Stock closed at $1.46 before this news, so the 30% jump makes sense if execution keeps up.